Valerio Therapeutics Société anonyme (LON:0NWK)

London · Delayed Price · Currency is GBP · Price in EUR

0.6890

+0.0240 (3.61%)

At close: Aug 11, 2026

969.88% (1Y)

Market Cap	292.66M +2,750.7%
Revenue (ttm)	2.24M +43.5%
Net Income	-4.27M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,333
Open	0.6670
Previous Close	0.6650
Day's Range	0.6670 - 0.7120
52-Week Range	0.0580 - 0.9800
Beta	2.07
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 26, 2026

About LON:0NWK

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, develops technology platforms dedicated to the targeted delivery of therapies. The company develops PlatON, a proprietary chemical platform for DNA decoy therapies, which generates new compounds and broadens its product portfolio; DecoyTAC, a mechanism of action of DNA decoy therapies coupled with targeted protein degradation; and V-body platform, a bispecific T-cell engagers, antibody– drug conjugates, and chimeric antigen receptors. The company was formerly known as... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1997

Employees 25

Stock Exchange London Stock Exchange

Ticker Symbol 0NWK

Financial Performance

In 2025, LON:0NWK's revenue was 2.57 million, an increase of 43.50% compared to the previous year's 1.79 million. Losses were -4.90 million, -79.53% less than in 2024.

Financial numbers in EUR Financial Statements